Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

Arcturus Therapeutics Holdings Inc. (ARCT) Market Cap & Valuation Ratios

Arcturus Therapeutics Holdings Inc. (ARCT) has a market cap of $279.7M and a price-to-sales ratio of 9.5, with earnings according to EquiReason's reading of its SEC filings.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

ARCTArcturus Therapeutics Holdings Inc.Follow ARCT — free
Biotechnology · Healthcare
—
Price chart with a free account
Market cap
279.7M
P/E TTM
—
Dividend yield
—
52-week
—
Next earnings
11 Nov, in 18 days

Peers

biotechnology · nearest by market cap · trailing 12 months
CompanyMkt cap, $BP/EEV/SalesEV/EBITDAFCF yieldRev. growthOp. marginROIC
ARCT0.3—3.0——-76%-348%—
AVIR0.3—0.3————-91%
ZURA0.3———————
XFOR0.3—12.8——-52%—-237%
FULC0.3——————-44%
FATE0.3—15.3——-23%—-78%
RCKT0.3——————-82%
OCGN0.3—51.3——-4%——
LRMR0.2——————-267%
VNDA0.2—0.9——+6%-86%-65%
DRUG0.2————+4943%——
Median of these 10—12.8——-4%-86%-82%

; EV/Sales 3.0 vs. 12.8.

Growth vs. price

each dot a company · hover or tap for values

Arcturus Therapeutics Holdings Inc. — questions

What is Arcturus Therapeutics Holdings Inc.'s market cap?
$279.7M.
What is Arcturus Therapeutics Holdings Inc.'s price-to-sales ratio?
9.5.

Every figure on this page comes from Arcturus Therapeutics Holdings Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.